Fund Details IssuerRoundhill Investments Fund NameRoundhill GLP-1 & Weight Loss ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:OZEM Inception Date5/20/2024 Fund ManagerWill Hershey, Tim Maloney, Dave Mazza, Drew Walsh Previous SymbolNASDAQ:OZEM WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings53 Fund Statistics Assets Under Management$0.00 Average Daily Volume$0.00 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorU.S
We conducted a retrospective analysis of the FDA Adverse Event Reporting System (FAERS) database from 2018 through 2024
Although many people who take Ozempic experience weight loss, it is not FDA-approved specifically for that purpose
PT-141 is FDA-approved for premenopausal women only and not postmenopausal women, and clinicians may consider its use in perimenopausal women on a case-by-case basis
Images Image 1: Courtesy of Steven Daveluy MD, FAAD Image 2: Courtesy of Lindsey Bordone, MD, FAAD Image 3: Property of American Academy of Dermatology References Lal K, Herringshaw E
Both peptides combine GLP-1 receptor activity with glucagon receptor activation, expanding opportunities to investigate multi-pathway metabolic signaling
